Recent Comments

Comment RSS

Hemophilia News and Research RSS Feed - Hemophilia News and Research

Hemophilia is a rare, inherited bleeding disorder in which your blood doesn’t clot normally. If you have hemophilia, you may bleed for a longer time than others after an injury. You also may bleed internally, especially in your knees, ankles, and elbows. This bleeding can damage your organs or tissues and, sometimes, be fatal.

Amsterdam Molecular Therapeutics provides third-quarter 2009 business updates

18. November 2009 04:03
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the third quarter of 2009. [More]

Lack of hemophilia treatment in the developing world costing lives

16. November 2009 07:23
When modern medicine finds a way to treat a medical condition, people often think that the problem is solved. But we also have to find ways to get that treatment into the hands of those who need it. For example, new research from North Carolina State University shows that much more needs to be done to help get existing treatment to hemophilia patients in the developing world, and that the current lack of treatment there is costing lives. [More]

Posted in: Medical Condition News | Healthcare News

Tags: ,

Lysteda tablets to treat menorrhagia approved by FDA

16. November 2009 00:07
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot. [More]

Baxter International lauds new Medicare education benefit for chronic kidney disease patients

10. November 2009 04:34
Baxter International Inc. commends the Centers for Medicare and Medicaid Services (CMS) on announcing implementation plans for a new Medicare benefit that will provide Stage 4 chronic kidney disease patients with coverage for up to six sessions explaining their treatment options, such as transplantation, home peritoneal dialysis (PD), home hemodialysis (HHD) or clinic-based hemodialysis (HD). [More]

Most patients with HAE have prodromal symptoms that signal an oncoming HAE attack

9. November 2009 01:52
Most patients with hereditary angioedema (HAE) have prodromal symptoms that signal an oncoming HAE attack giving the patients sufficient time to initiate treatment and decrease the morbidity associated with that attack, according to survey findings presented today at the 2009 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. [More]

C1-INH concentrate, an effective therapy to treat acute swelling attacks at any body location for HAE

9. November 2009 00:11
Patients reported C1-esterase inhibitor (C1-INH) concentrate is an effective therapy in treating acute swelling attacks at any body location for HAE, a rare and serious genetic disorder, according to data presented today at the 2009 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. [More]

GTC Biotherapeutics announces financial results for third quarter 2009

6. November 2009 23:49
GTC Biotherapeutics, Inc.’s total net loss for the third quarter ended September 27, 2009 was $5.1 million, or $0.48 per share, compared with $6.1 million, or $0.59 per share, in the third quarter of 2008. The total net loss for the first nine months of 2009 was $26.2 million, or $2.51 per share, compared to $16.5 million, or $1.71 per share, for the first nine months of 2008. [More]

Posted in: Business / Finance

Tags: , , ,

Gene therapy saves 2 children with adrenoleukodystrophy

6. November 2009 03:02
The ELA association and Zinedine Zidane, its emblematic ambassador, are proud to announce a world premiere: the results regaring the gene therapy in adrenoleukodystrophy conducted in France have just been published in the prestigious journal Science. Two children have been treated and their diseases have been halted. The children are doing well, which is unexpected for a disease destroying the brain in a few months. This discovery opens up treatment perspectives for numerous widespread diseases. [More]

LFB Biotechnologies exercises its option to purchase $12.8 million of stocks in GTC Biotherapeutics

2. November 2009 10:27
GTC Biotherapeutics, Inc. announced that LFB Biotechnologies, a wholly owned subsidiary of LFB S.A. (Laboratoire français du Fractionnement et des Biotechnologies S.A., Les Ulis, France) and a strategic shareholder in GTC, has exercised its option to purchase $12.8 million of additional convertible preferred stock under the terms described in the financing agreements approved by GTC shareholders in July 2009. This transaction provides $6.4 million of new cash proceeds to GTC. [More]

Posted in: Business / Finance

Tags: , , , , , , ,

Novo Nordisk re-launches its changing possibilities in hemophilia campaign

31. October 2009 01:52
Novo Nordisk Inc. announced the re-launch of its changing possibilities in hemophilia(TM) campaign through a rebranded Web site and a new community on Facebook®. People living with hemophilia face many daily challenges, and Novo Nordisk is committed to helping this community realize that there is also a lifetime of possibilities. [More]

Posted in: Device / Technology News | Medical Condition News

Tags: , , , , ,

NYBC and its divisions call upon the community to join the fight against cancer by donating blood

31. October 2009 00:41
November is both Pancreatic Cancer Awareness Month and Lung Cancer Awareness Month, and New York Blood Center (NYBC) and its divisions in Manhattan, Long Island, Hudson Valley, Brooklyn/Staten Island, and New Jersey call upon the community to join the fight against cancer by donating blood today. [More]

Posted in: Medical Condition News

Tags: , , , , , ,

Phase 2a clinical trial in nonsense mutation hemophilia A and hemophilia B initiated

26. October 2009 08:42
PTC Therapeutics, Inc. (PTC) today announced it is expanding the development of ataluren, an investigational new drug, to a third indication with the initiation of a Phase 2a clinical trial in nonsense mutation hemophilia A (nmHA) and hemophilia B (nmHB). [More]

Posted in: Drug Trial News

Tags: , , , , , , , ,

Medgenics signs $7 million agreement to develop the Biopump technology for Factor VIII

23. October 2009 06:09
Medgenics is pleased to announce that it has signed a preclinical development and option agreement with a major international biopharmaceutical company that is a market leader in the field of hemophilia. [More]

Accredo Health Group announces a 10-year renewal of its headquarters with Memphis

22. October 2009 08:39
Accredo Health Group Inc. announced a 10-year renewal of its 240,000-square-foot headquarters at Century Center, positioning the nation's largest specialty pharmacy and a major fixture of Memphis' health care industry for future growth. The General Investment & Development Companies and Accredo agreed to renew all leases for Accredo's five-building campus, effective January 1, 2010. [More]

Biogen Idec announces total revenues of $1.12 billion for third quarter 2009

20. October 2009 07:35
Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today reported its third quarter 2009 results. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.